Report : Europe Immunodiagnostics Market Forecast to 2030 – Regional Analysis – by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

At 7.4% CAGR, the Europe Immunodiagnostics Market is speculated to be worth US$ 10,098.03 million by 2030, says Business Market Insights

According to Business Market Insights Research, the Europe immunodiagnostics market was valued at US$ 6,131.85 million in 2023 and is expected to reach US$ 10,098.03 million by 2030, registering a CAGR of 7.4% from 2023 to 2030. Growing use of point-of-care immunodiagnostics and increasing prevalence of infectious diseases are the critical factors attributed to the Europe immunodiagnostics market expansion.

Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the Europe immunodiagnostics market. Several market players are developing innovative immunodiagnostic products. For instance, Thermo Fisher Scientific has developed immunodiagnostic products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.

In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes. Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostic test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the Europe immunodiagnostics market.  

On the contrary, inadequate reimbursement scenario hurdles the growth of Europe immunodiagnostics market.

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.3% share of Europe immunodiagnostics market in 2023, amassing US$ 3,393.40 million. It is projected to garner US$ 5,523.28 million by 2030 to expand at 7.2% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 44.9% share of Europe immunodiagnostics market in 2023, amassing US$ 2,755.78 million. It is projected to garner US$ 4,711.65 million by 2030 to expand at 8.0% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.3% share of Europe immunodiagnostics market in 2023, amassing US$ 2,654.93 million. It is projected to garner US$ 4,295.46 million by 2030 to expand at 7.1% CAGR during 2023–2030.  

Based on country, the Europe immunodiagnostics market is segmented into Based on country, the Europe immunodiagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.3% share of Europe immunodiagnostics market in 2023. It was assessed at US$ 1,799.08 million in 2023 and is likely to hit US$ 2,885.01 million by 2030, exhibiting a CAGR of 7.0% during 2023–2030.  

Key players operating in the Europe immunodiagnostics market report Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure